TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Market Opportunity
    • Investor Relations Email Alerts
    • Company Information
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Contact
    • Investors Relations FAQ
  • Contacts

News and Media

Theralink   →  Media Room
Posted on November 24, 2020November 24, 2020

Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.

DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision o...
Read More
Posted on September 30, 2020December 10, 2020

Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer

DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular...
Read More
Posted on September 24, 2020December 10, 2020

Theralink® Technologies Announces Corporate Name Change

  DENVER, Colorado — September 24, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), fo...
Read More
Posted on September 15, 2020October 21, 2020

OncBioMune d/b/a Theralink® Technologies Announces Strategic Translational Research Collaboration with BioMed Valley Discoveries

Golden, Colorado – September 15th, 2020 – Theralink Technologies, Inc., a molecular profiling company (OTC: OBMP), today annou...
Read More
Posted on September 10, 2020September 10, 2020

H.C. Wainwright 22nd Annual Global Investment Conference

Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to...
Read More
Posted on September 10, 2020September 18, 2020

Theralink® Technologies to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Compan...
Read More
Posted on September 9, 2020

Theralink® Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory

Expects to Begin Receiving, Testing and Billing for Patient’s Breast Cancer Tumor Specimens in Q4 2020 -- DENVER, Colorado...
Read More
Posted on August 25, 2020

Theralink® Technologies to Present at the LD 500 Virtual Conference on September 1st

DENVER, Colorado — August 25, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company...
Read More
Posted on July 22, 2020December 10, 2020

Theralink® Technologies Appoints Michael Fanelli Senior Director, Biopharma Commercial Operations

  Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring...
Read More
Posted on July 8, 2020March 28, 2022

Theralink® Technologies Announces Strategic Agreement with VieCure to Improve Outcomes for Breast Cancer Patients Being Treated in Community Oncology Settings

  Theralink® Technologies Announces Strategic Agreement with VieCure to Improve Outcomes for Breast Cancer Patients Being...
Read More
Previous page 1 2 3 Next page

Recent Posts

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
  • Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies’ Lab Developed Test for Advanced Breast Cancer Patients
  • Theralink® Technologies Announces Change of Ticker Symbol and CUSIP
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Copyright © 2022 Theralink. All rights reserved.